Dopamine Signaling Pathway

Canonical source: hsa04728

Pathway Overview

Dopamine signaling regulates reward, motivation, movement, cognition, and psychosis. Dopamine is synthesized in substantia nigra and ventral tegmental area; released into striatum and prefrontal cortex. DRD2 is the primary postsynaptic receptor in mesolimbic and nigrostriatal pathways; D2 antagonists are antipsychotics. Dopamine is metabolized by COMT and MAO. Hyperdopaminergia in striatum is implicated in schizophrenia; hypodopaminergia in addiction. DRD2 variants influence receptor density, antipsychotic response, and addiction vulnerability. Psychosocial stress and substance use (alcohol, tobacco) modulate dopamine signaling and interact with genetic susceptibility.

Environmental Triggers

Exposure	Trigger type
psychosocial-stress	Chronic stress alters dopaminergic tone and prefrontal-striatal balance
alcohol	Alcohol acutely increases dopamine; chronic use causes neuroadaptation
tobacco	Nicotine stimulates dopaminergic reward circuitry

Genetic Modulation Points

Key genes

drd2— D2 dopamine receptor; primary target of antipsychotics; variants affect receptor function and addiction risk
slc6a4— Serotonin transporter; modulates dopamine-serotonin interaction; relevant to comorbid depression and addiction

Regulatory checkpoints

D2 receptor signaling— drd2Therapeutic target
Dopamine reuptake— slc6a4Therapeutic target

Tissue Specificity

striatum— Primary site of DRD2; reward and movement

prefrontal cortex— Executive function; working memory

Disease Relevance

Linked diseases

schizophrenia— Hyperdopaminergia hypothesis; DRD2 is antipsychotic target
major-depressive-disorder— Dopamine-serotonin interaction; anhedonia and motivation

Linked exposures

alcohol— Alcohol dependence involves dopamine dysregulation; DRD2 variants
psychosocial-stress— Stress precipitates psychosis and depression; gene-environment interaction

Pathway Diagram

Pathway diagram placeholder. A visual representation of this pathway will be integrated when available.

Evidence Nodes

Evidence for this pathway is derived from:

3 environmental trigger(s)
2 key gene(s)
2 linked disease(s)
2 linked exposure(s)

References

1.Howes OD, Kapur S (2009). DRD2 and schizophrenia. Schizophrenia Bulletin. doi:10.1093/schbul/sbp075
2.Volkow ND, et al. (2007). Dopamine and addiction. Nature Reviews Neuroscience. doi:10.1038/nrn2339
3.Cabib S, Puglisi-Allegra S (2012). Stress, dopamine, and psychiatric illness. Neuroscience & Biobehavioral Reviews. doi:10.1016/j.neubiorev.2011.09.008
4.Munafo MR, et al. (2007). DRD2 polymorphisms and substance use. Addiction Biology. doi:10.1111/j.1369-1600.2006.00041.x